Table 1 Characteristics of 231 patients studied and comparison among PNPLA3 genotypes
From: PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients
| Â | All patients | Patients with GG | Patients with CC or CG | Comparison between patients with GG and those with CG or CG |
|---|---|---|---|---|
(n = 231) | (n = 41) | (n = 190) | ||
Age (yrs) | 62.9 ± 11.3 | 63.8 ± 10.6 | 62.7 ± 11.5 | NS |
Gender (male/female) | 103/128 | 19/22 | 84/106 | NS |
BMI (kg/m2) | 22.5 ± 3.5 | 23.3 ± 3.6 | 22.3 ± 3.5 | NS |
Response to IFN treatment (NVR/no past IFN therapy) | 94/137 | 19/22 | 75/115 | NS |
PNPLA3 (GG/CG/CC) | 41/118/72 | Â | Â | Â |
AST (IU/L) | 57.0 ± 48.8 | 68.5 ± 61.9 | 54.5 ± 45.3 | p = 0.0946 |
ALT (IU/L) | 62.9 ± 76.1 | 63.8 ± 51.6 | 62.7 ± 80.5 | NS |
γ-GTP (IU/L) | 58.9 ± 78.1 | 60.6 ± 63.5 | 58.5 ± 81.0 | NS |
Albumin (g/dL) | 4.1 ± 0.6 | 4.0 ± 0.6 | 4.1 ± 0.6 | NS |
Total bilirubin (mg/dL) | 1.0 ± 0.8 | 1.2 ± 0.8 | 0.9 ± 0.8 | p = 0.0876 |
Platelet count (x104/μL) | 13.4 ± 5.6 | 11.7 ± 5.4 | 13.8 ± 5.5 | p = 0.0276 |
Prothrombin time (%) | 94.3 ± 18.6 | 88.9 ± 17.7 | 95.5 ± 18.7 | p = 0.0407 |
Hyaluronic acid (ng/mL) | 236.6 ± 337.7 | 340.5 ± 490.3 | 214.5 ± 292.3 | p = 0.0365 |
α-fetoprotein (ng/mL) | 79.1 ± 529.3 | 66.3 ± 193.5 | 81.9 ± 578.0 | NS |
PIVKA-II(mAU/mL) | 24.7 ± 23.1 | 29.3 ± 36.4 | 23.7 ± 18.9 | NS |
HCV genotype (1/2/3) | 188/41/2 | 34/7/0 | 150/37/2 | NS |
HCV RNA (log IU/mL) | 6.1 ± 1.0 | 6.1 ± 1.3 | 6.1 ± 1.0 | NS |
Velocity of shear wave (m/s) | 1.66 ± 0.52 | 1.91 ± 0.70 | 1.65 ± 0.57 | p = 0.0126 |
Hepatocellular carcnoma (present/absent) | 48/183 | 14/27 | 22/96 | p = 0.0200 |